Final Program

WEDNESDAY • MAY 18 345
10:45 Comparing Patient-Reported Outcomes to Functional,
Hemodynamic, Echocardiographic, and Cardiac MRI
Parameters in Scleroderma-Associated Pulmonary Arterial
Hypertension/R. Khair, T. Kolb, R.L. Damico, P.M. Hassoun, R.T.
Zamanian, R. Tedford, T. Housten Harris, T. Sato, E. Pullins, C.
Corona-Villalobos, S.L. Zimmerman, O. Minai, F. Torres, R.E.
Girgis, K.M. Chin, S.C. Mathai, Baltimore, MD, p.A6469
D21
POSTER DISCUSSION SESSION
ASTHMA TREATMENT: GLUCOCORTICOIDS,
BIOLOGICALS AND BEYOND
9:00 a.m. - 11:00 a.m. MOSCONE CENTER
Room 2010/2012 (West Building, Level 2)
Poster Viewing 9:00-9:45
Discussion 9:45-11:00
Chairing: S.E. Wenzel, MD, Pittsburgh, PA
L.E. Cohn, MD, New Haven, CT
N.J. Kenyon, MD, Sacramento, CA
401 Effect of Mepolizumab in Severe Eosinophilic Asthma Patients
Eligible for Omalizumab Treatment/F.C. Albers, R. Price, S.
Yancey, E. Bradford, Research Triangle Park, NC, p.A6470
402 Burden of Disease in Severe Asthma Mepolizumab Population
Stratified by Blood Eosinophil Count/E. Bradford, R. Follows, R.
Price, S. Yancey, Research Triangle Park, NC, p.A6471
403 Utility of Serum Periostin and Free IgE Levels in Evaluating
Responsiveness to Omalizumab in Patients with Severe
Asthma/T. Tajiri, H. Matsumoto, Y. Gon, R. Ito, S. Hashimoto, K.
Izuhara, M. Suzukawa, K. Ohta, J. Ono, S. Ohta, I. Ito, T. Oguma,
H. Inoue, T. Iwata, T. Nagasaki, Y. Kanemitsu, A. Niimi, M.
Mishima, Kyoto, Japan, p.A6472
404 Baseline IgE Levels as a Marker of Type 2 Asthma Among
Patients Enrolled in the Prospective Observational Study to
Evaluate Predictors of Clinical Effectiveness in Response to
Omalizumab (PROSPERO)/B.E. Chipps, W.W. Busse, A.T.
Luskin, R.S. Zeiger, B. Trzaskoma, N.M. Griffin, T.A. Omachi, T.B.
Casale, Sacramento, CA, p.A6473
405 Omalizumab - Response in Patients with Severe Allergic
Asthma in a Real Life Setting/L. Zierau, E.S. Walsted, V. Backer,
Copenhagen, Denmark, p.A6474
406 Regulating Goblet Cell Formation and Mucus Production with
Inhaled Sam Pointed Domain Containing ETS Transcription
Factor (SPDEF) Antisense Oligonucleotides/J. Crosby, C. Zhao,
D. Bai, M. McCaleb, S. Guo, B.P. Monia, Carlsbad, CA, p.A6475
407 A Randomized, Double-Blinded, Placebo-Controlled,
Ascending Dose Study of the Safety, Tolerability, and
Pharmacokinetics of XmAbr7195/A. Gershman, R. Goldwater, P.
Foster, San Diego, CA, p.A6476
408 L-Arginine and Glucagon-Like Peptide 1, a Novel Pathway to
Asthma Control/D.-V. Nguyen, A.L. Linderholm, L. Franzi, N.J.
Kenyon, Sacramento, CA, p.A6477
409 The Effect of the 15-Lipoxygenase 1 (15LO1) Inhibitor BLX2477
on IL-13-Induced Periostin mRNA Expression in Human Airway
Epithelial Cells (HAECs)/Y. Minami, E.B. Etling, V.B. O’Donnell,
E.B. Yecies, J.B. Trudeau, H.E. Claesson, J. Zhao, S.E. Wenzel,
Pittsburgh, PA, p.A6478
410 Inhibition of Asthma Phenotype Through Aerobic Exercise:
Involvement of P2X7 Receptor and CD73 Signaling in Airway
Epithelium and in Peribronchial Leukocytes/R.P. Vieira, M.C.
De Oliveira Junior, A.R. Almeida-Oliveira, J.C.J. Aquino-Junior,
A.S. Andrade-Sousa, E. Assumpcao-Neto, A. Aparecida-Brito, N.C.
Rigonato-Oliveira, A.S. Renno, M.A.R. Brandao-Rangel, A.P.L.
Oliveira, Sao Paulo, Brazil, p.A6479
411 Aerobic Exercise Reduces Asthma Phenotype Through
Modulation of SOCS-JAK-STAT Signaling/R.P. Vieira, A.R.
Almeida-Oliveira, J.C.J. Aquino-Junior, M.C. Oliveira-Junior, A.S.
Andrade-Sousa, E. Assumpcao-Neto, A. Aparecida-Brito, N.C.
Rigonato-Oliveira, A. Silva-Renno, M.A.R. Brandao-Rangel, A.P.L.
Oliveira, Sao Paulo, Brazil, p.A6480
412 Anti-Inflammatory Effect of an Eicosapentaenoic Acid
Metabolite on Airway Inflammation in a Murine Model of
Ovalbumin-Induced Asthma/T. Mochimaru, K. Fukunaga, J.
Miyata, M. Matsusaka, K. Masaki, H. Kabata, Y. Suzuki, Y. Isobe,
M. Arita, T. Betsuyaku, Tokyo, Japan, p.A6481
413 Selective Targeting of STAT6 at Antigen Priming Reduces
OX40L and TH2-Biased Airway Inflammatory Responses/S.
Lee, J. Shan, B.T. Srinivasa, M. Jin, E.D. Fixman, Montrea,
Canada, p.A6482
414 Pre-Clinical Evaluation of a Potent Janus Kinase (JAK)
Inhibitor Designed for Topical Delivery in Severe Asthma/H.-H.
Lee, M.A. Gil, J. Woodhouse, M. Caniga, A. Byford, R. McLeod, Y.
Jia, R. Fernandes, J. Naber, D. Witter, M. Cicmil, M. Salmon,
Boston, MA, p.A6483
415 Developing FOXM1 Inhibitors to Suppress Goblet Cell
Metaplasia and Airways Hyperresponsiveness/V. Kalinichenko,
L. Sun, X. Ren, I.-C. Wang, A. Pradhan, Y. Zhang, B. Han, J.A.
Whitsett, T.V. Kalin, Cincinnati, OH, p.A6484
416 A Randomised, Double-Blind, Placebo-Controlled Study to
Evaluate the Efficacy of Oral Azithromycin (500 Mg OD) as a
Supplement to Standard Care for Adult Patients with Acute
Exacerbations of Asthma (the AZALEA Trial)/S.L. Johnston, M.
Szigeti, M. Cross, C.E. Brightling, R. Chaudhuri, T. Harrison, A.H.
Mansur, L. Robinson, Z. Sattar, D.J. Jackson, P. Mallia, E.H.C.
Wong, C. Corrigan, B. Higgins, P. Ind, D. Singh, N.C. Thomson, D.
Ashby, A. Chauhan, London, United Kingdom, p.A6485
417 Effect of Dupilumab on FEV1 and Severe Exacerbations in
Patients with Uncontrolled Persistent Asthma: A Subgroup
Analysis Defined According to Early-Onset and Late-Onset
Asthma/S.F. Weinstein, L.B. Ford, B. Zhang, G. Pirozzi, H.
Staudinger, R.R. Evans, N.M.H. Graham, M. Louis-Tisserand, A.
Teper, Huntington Beach, CA, p.A6486
418 Roflumilast Ameliorates Airway Hyper-Responsiveness
Caused by Diet-Induced Obesity in a Murine Model/H.J. Park,
J.-H. Lee, Y.H. Park, H. Han, D.W. Sim, K.H. Park, J.-W. Park,
Seoul, Korea, Republic of, p.A6487
WEDNESDAY MORNING
ATS 2016 • San Francisco